Related Experiment Videos
Serum copper in ovarian carcinoma
A J Jacobs1, G M Sommers, J H Axelrod
1Department of Obstetrics and Gynecology, St. Louis University School of Medicine, MO 63104.
Cancer
|March 1, 1988
Summary
Serum CA 125 levels correlate with epithelial ovarian carcinoma progression, unlike serum copper. Serum copper testing is not useful for managing this cancer.
Area of Science:
- Oncology
- Biochemistry
Background:
- Epithelial ovarian carcinoma is a significant cause of cancer-related mortality.
- Biomarkers are crucial for monitoring cancer progression and treatment efficacy.
Purpose of the Study:
- To evaluate the clinical utility of serum copper and CA 125 as biomarkers in epithelial ovarian carcinoma.
- To determine if serum copper levels correlate with disease progression in these patients.
Main Methods:
- Serum samples were collected from 31 patients diagnosed with epithelial ovarian carcinoma.
- Serum copper and cancer antigen 125 (CA 125) levels were measured.
- Correlations between biomarker levels and disease progression were analyzed.
Main Results:
- Elevated serum CA 125 was observed in 22 out of 31 patients and consistently indicated disease progression.
- Elevated serum copper was found in 7 patients, but its levels did not correlate with the malignancy's natural history.
- Serum copper fluctuations showed no association with disease progression or patient outcomes.
Conclusions:
- Serum CA 125 is a valuable biomarker for monitoring epithelial ovarian carcinoma progression.
- Serum copper levels lack clinical utility in the management of epithelial ovarian carcinoma.
- Further research may explore other potential roles for copper in gynecologic cancers, but its current utility as a standalone marker is limited.